The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate mRNA sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the mRNA vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the mRNA vaccine immunotherapy on human cancers will firstly be evaluated.

Start Date08 May 2024

Sponsor / Collaborator

Second Affiliated Hospital of Guangzhou Medical University

100 Clinical Results associated with Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University)

100 Translational Medicine associated with Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University)

100 Patents (Medical) associated with Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University)

Literatures (Medical) associated with Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University)

11 Oct 2024·Science Advances

Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity

Article

Author: Huang, Lei ; Wang, Qiuhe ; Tang, Dean G. ; Xu, Zhuya ; Liang, Shujing ; Zhong, Zhixian ; Xu, Mingcheng ; Dong, Chunyan ; Ren, Jiale ; Yang, Jingxian ; Xu, Congcong ; Wu, Jichuan ; Jamroze, Anmbreen ; Shen, Haifa ; Fan, Ting ; Zhu, Zhounan ; Chen, Chunxiu ; Tang, Yuying ; Zhu, Hanfei ; Cai, Yihua ; Ma, Xiaopin ; Yu, Bo ; Chen, Fengjia ; Li, Qianyun ; Cao, Wanlu ; Zhang, Mingna ; Li, Hangwen

mRNA neoantigen cancer vaccine inducing neoantigen-specific T cell responses holds great promise for cancer immunotherapy; however, its clinical translation remains challenging because of suboptimal neoantigen prediction accuracy and low delivery efficiency, which compromise the in vivo therapeutic efficacy. We present a lipopolyplex (LPP)–formulated mRNA cancer vaccine encoding tandem neoantigens as a cancer therapeutic regimen. The LPP-formulated mRNA vaccines elicited robust neoantigen-specific CD8 + T cell responses in three syngeneic murine tumor models (CT26, MC38, and B16F10) to suppress tumor growth. Prophylactic cancer vaccine treatment completely prevented tumor development, and long-lasting memory T cells protected mice from tumor cell rechallenge. Combining the vaccine with immune checkpoint inhibitor further boosted the antitumor activity. Of note, LPP-based personalized cancer vaccine was administered in two cancer patients and induced meaningful neoantigen-specific T cell and clinical responses. In conclusion, we demonstrated that the LPP-based mRNA vaccine can elicit strong antitumor immune responses, and the results support further clinical evaluation of the therapeutic mRNA cancer vaccine.

01 Apr 2024·Med

Melanoma neoantigen vaccines: Are we getting more personal now?

Article

Author: Haanen, John B ; Latifyan, Sofiya

KEYNOTE-942¹ is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.

01 Mar 2024·Nature Reviews Clinical Oncology

Personalized neoantigen mRNA vaccine mitigates melanoma recurrence

Article

Author: Killock, David

100 Deals associated with Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	CN	Second Affiliated Hospital of Guangzhou Medical University	08 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation